S100P Protein

Catalog No. ABIN7669564

This Recombinant S100P protein is produced in Escherichia coli (E. coli).

Quick Overview for S100P Protein (ABIN7669564)

Target: S100P (S100 Calcium Binding Protein P (S100P))

Protein Type: Recombinant

Biological Activity: Inactive

Origin: Human

Source: Escherichia coli (E. coli)

Purity: > 97 %

Product Details

Purpose: Recombinant Human S100P/S100E Protein

Sequence: Met 1-Lys 95

Purification: > 97 % as determined by reducing SDS-PAGE.

Sterility: 0.2 μm filtered

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.5
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Expiry Date: 12 months

Target Details

Target: S100P (S100 Calcium Binding Protein P (S100P))

Alternative Name: S100P

Background: Protein S100-P, also known as Protein S100-E, S100 calcium-binding protein P, S100P and S100E, is a nucleus and cytoplasm protein which belongs to theS-100 family. S100P / S100E contains twoEF-hand domains. S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction, protein phosphorylation and transcriptional control. S100P / S100E overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. S100P / S100E may directly confer resistance to chemotherapy. S100P / S100E induction may be considered an important step in the initial stage of lung adenocarcinomas, whereas its downregulation in advanced stages seems to be important for tumour progression in which DNA methylation and/or feedback transcription processes play a critical role. S100P / S100E plays a major role in the aggressiveness of pancreatic cancer that is likely mediated by its ability to activate RAGE. Interference with S100P / S100E may provide a novel approach for treatment of pancreatic cancer. S100P / S100E could be considered a potential drug target or a chemosensitization target, and could also serve as a biomarker for aggressive, hormone-refractory and metastatic prostate cancer.,MIG9,Protein S100-E,Protein S100-P,S100 Calcium-Binding Protein P,S100E,S100P

Molecular Weight: 10.4 kDa

UniProt: P25815

Pathways: Regulation of Muscle Cell Differentiation, Toll-Like Receptors Cascades, S100 Proteins